Literature DB >> 10903413

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.

E Sacchetti1, L Guarneri, D Bravi.   

Abstract

BACKGROUND: Olanzapine is temporally associated, in a number of patients with schizophrenia, with weight gain. H(2) antagonists, like nizatidine, have been shown to control appetite in overweight patients.
METHODS: A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy.
RESULTS: Nizatidine treatment was associated with good control and subsequent reduction of weight after 4 to 5 weeks of therapy in a patient with repetitive episodes of weight gain during olanzapine treatment. Olanzapine was otherwise well tolerated and effective in controlling psychopathology.
CONCLUSIONS: H(2) antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia. Controlled studies are recommended to confirm this observation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903413     DOI: 10.1016/s0006-3223(00)00872-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

Review 1.  Treatment-refractory schizophrenia.

Authors:  P F Buckley; L D Wiggins; S Sebastian; B Singer
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Weight gain and new onset diabetes associated with olanzapine and risperidone.

Authors:  Wildon R Farwell; Timothy E Stump; Jane Wang; Eskinder Tafesse; Gilbert L'Italien; William M Tierney
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

Review 4.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 5.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

7.  Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities.

Authors:  Kimberly D McLaren; Lauren B Marangell
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-04-22

8.  The effect of ranitidine on olanzapine-induced weight gain.

Authors:  Fatemeh Ranjbar; Alireza Ghanepour; Homayoun Sadeghi-Bazargani; Mahbob Asadlo; Amineh Alizadeh
Journal:  Biomed Res Int       Date:  2013-07-30       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.